CTLA4 and cancer: ICIs act by targeting key immune regulatory pathways, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and programmed death ligand 1 (PD-L1), thereby enhancing the immune system’s ability to detect and eliminate cancer cells (2).